age float64 18 102 | sex stringclasses 2
values | hospdead int64 0 1 | slos int64 3 343 | dzgroup stringclasses 8
values | dzclass stringclasses 4
values | num.co int64 0 9 | edu float64 0 31 ⌀ | income stringclasses 4
values | scoma float64 0 100 ⌀ | charges float64 1.17k 1.44M ⌀ | totcst float64 0 633k ⌀ | totmcst float64 -102.72 711k ⌀ | avtisst float64 1 83 ⌀ | race stringclasses 5
values | sps float64 0.2 99.2 ⌀ | aps float64 0 143 ⌀ | surv2m float64 0 0.97 ⌀ | surv6m float64 0 0.95 ⌀ | hday int64 1 148 | diabetes int64 0 1 | dementia int64 0 1 | ca stringclasses 3
values | prg2m float64 0 1 ⌀ | prg6m float64 0 1 ⌀ | dnr stringclasses 3
values | dnrday float64 -88 285 ⌀ | meanbp float64 0 195 ⌀ | wblc float64 0 200 ⌀ | hrt float64 0 300 ⌀ | resp float64 0 90 ⌀ | temp float64 31.7 41.7 ⌀ | pafi float64 12 890 ⌀ | alb float64 0.4 29 ⌀ | bili float64 0.1 63 ⌀ | crea float64 0.1 21.5 ⌀ | sod float64 110 181 ⌀ | ph float64 6.83 7.77 ⌀ | glucose float64 0 1.09k ⌀ | bun float64 1 300 ⌀ | urine float64 0 9k ⌀ | adlp float64 0 7 ⌀ | adls float64 0 7 ⌀ | sfdm2 stringclasses 5
values | adlsc float64 0 7.07 | event_times int64 3 2.03k | event_indicators int64 0 1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
71.66095 | male | 0 | 11 | Colon Cancer | Cancer | 2 | 18 | under $11k | 0 | 20,083 | 11,667.2031 | 10,053 | 7.5 | hispanic | 17.597656 | 13 | 0.795898 | 0.56897 | 1 | 0 | 0 | metastatic | null | null | no dnr | 11 | 103 | 12 | 84 | 16 | 36.59375 | null | 3.899902 | 0.599976 | 0.899902 | 139 | null | 140 | 8 | 4,150 | null | 1 | no(M2 and SIP pres) | 1 | 313 | 1 |
70.59497 | male | 0 | 17 | MOSF w/Malig | ARF/MOSF | 1 | 17 | null | 0 | 44,516 | null | null | 21.666656 | white | 30.097656 | 42 | 0.5 | 0.382996 | 3 | 0 | 0 | yes | 0.8 | 0.7 | no dnr | 17 | 57 | 0.099991 | 146 | 27 | 35.89844 | 177.5 | 2.199707 | 0.799927 | 4.5 | 142 | 7.349609 | 209 | 97 | 185 | null | 1 | <2 mo. follow-up | 1 | 26 | 1 |
47.75598 | male | 1 | 7 | Coma | Coma | 1 | null | null | 44 | 20,038 | null | null | 24 | black | 20.796875 | 35 | 0.716919 | 0.664917 | 1 | 0 | 0 | no | null | null | dnr after sadm | 4 | 117 | 11.599609 | 134 | 21 | 37.09375 | 274.25 | null | 0.5 | 2.099609 | 135 | 7.369141 | 97 | 67 | 2,030 | null | null | <2 mo. follow-up | 1.883301 | 7 | 1 |
49.52197 | female | 0 | 9 | MOSF w/Malig | ARF/MOSF | 1 | 14 | $25-$50k | 0 | 53,838 | null | null | 16.5 | white | 25.296875 | 43 | 0.540894 | 0.426941 | 9 | 0 | 0 | metastatic | null | null | no dnr | 9 | 117 | 10.5 | 64 | 10 | 38.39844 | 312 | null | null | 0.599976 | 141 | 7.399414 | 111 | 7 | 4,050 | 0 | 1 | no(M2 and SIP pres) | 1 | 1,026 | 0 |
67.50397 | female | 0 | 8 | Lung Cancer | Cancer | 1 | 14 | >$50k | 0 | 12,570 | null | null | 18 | white | 28.5 | 13 | 0.406982 | 0.107986 | 1 | 0 | 0 | metastatic | null | null | no dnr | 8 | 130 | 7.5 | 116 | 26 | 36 | 323.3125 | null | 0.599976 | 1.5 | 138 | 7.399414 | 253 | 44 | 2,350 | 6 | 7 | null | 7 | 64 | 1 |
45.89999 | male | 0 | 12 | Lung Cancer | Cancer | 0 | 10 | $11-$25k | 0 | 10,337 | null | null | 7 | hispanic | 28.796875 | 12 | 0.472961 | 0.156982 | 1 | 0 | 0 | metastatic | 0.8 | 0.6 | no dnr | 12 | 71 | 6.699219 | 54 | 20 | 36.5 | null | null | null | 1.199951 | 138 | null | 72 | 12 | 2,160 | 0 | 0 | no(M2 and SIP pres) | 0 | 212 | 1 |
35.099 | male | 0 | 15 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 12 | null | 61 | 50,602 | null | null | 18 | white | 30.597656 | 52 | 0.611938 | 0.505981 | 1 | 0 | 0 | no | 0.6 | 0.5 | no dnr | 15 | 69 | 10.599609 | 70 | 12 | 36.5 | 253.3125 | null | null | 0.899902 | 134 | 7.469727 | 130 | 23 | 1,170 | null | 5 | SIP>=30 | 5 | 1,025 | 0 |
50.43399 | female | 0 | 25 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | 9 | null | 0 | 155,353 | null | null | 33.25 | black | 29.5 | 54 | 0.700928 | 0.610962 | 20 | 0 | 0 | no | 0.6 | 0.5 | no dnr | 25 | 76 | 16.898438 | 126 | 32 | 37.69531 | 105 | null | null | 1 | 137 | 7.479492 | 134 | 22 | 3,320 | null | 0 | null | 0 | 61 | 1 |
65.23999 | male | 1 | 58 | MOSF w/Malig | ARF/MOSF | 1 | 16 | $25-$50k | 44 | 205,279 | null | null | 33.5 | white | 32.296875 | 57 | 0.161987 | 0.079987 | 14 | 0 | 0 | yes | null | null | dnr after sadm | 49 | 58 | 11 | 96 | 36 | 36.59375 | 304 | null | null | 2.099609 | 133 | 7.509766 | 165 | 60 | 4,485 | null | 0 | <2 mo. follow-up | 0 | 58 | 1 |
74.57397 | female | 1 | 5 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 12 | under $11k | 0 | 93,795 | null | null | 41 | white | 45 | 76 | 0.078995 | 0.029999 | 20 | 0 | 0 | yes | 0.2 | 0.05 | no dnr | 5 | 73 | 5.799805 | 70 | 16 | 36.5 | null | 3.899902 | 1.899902 | 1.299805 | 136 | null | 155 | 25 | 1,400 | null | 1 | <2 mo. follow-up | 1 | 5 | 1 |
67.81696 | male | 1 | 8 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 11 | >$50k | 0 | 53,038 | null | null | 47 | white | 49 | 82 | 0.155975 | 0.075989 | 2 | 0 | 0 | no | 0.6 | 0.4 | dnr after sadm | 6 | 79 | 10 | 70 | 20 | 36.79688 | null | null | 0.899902 | 1.5 | 142 | null | 153 | 22 | null | null | 0 | <2 mo. follow-up | 0 | 8 | 1 |
79.21698 | female | 0 | 71 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 8 | $11-$25k | 0 | 175,574 | 120,693.125 | 87,405 | 40.25 | white | 27.398438 | 37 | 0.688965 | 0.596924 | 1 | 0 | 0 | no | 0.5 | 0.45 | no dnr | 71 | 103 | 9.398438 | 114 | 35 | 36.39844 | 433.3125 | null | null | 0.899902 | 131 | 7.429688 | 343 | 13 | 1,555 | null | 0 | SIP>=30 | 0 | 1,023 | 0 |
70.75696 | male | 1 | 8 | COPD | COPD/CHF/Cirrhosis | 0 | 3 | $11-$25k | 41 | 39,964 | null | null | 35.5 | white | 27.097656 | 43 | 0.490967 | 0.28894 | 6 | 0 | 0 | no | 0.25 | 0.05 | dnr after sadm | 4 | 63 | 6.299805 | 116 | 20 | 38.19531 | null | null | 0.599976 | 0.599976 | 139 | null | 96 | 8 | null | null | 0 | <2 mo. follow-up | 0 | 8 | 1 |
65.74097 | male | 0 | 40 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 12 | null | 0 | 144,457 | 96,665.3125 | 75,360 | 24.5 | white | 22.5 | 27 | 0.778931 | 0.706909 | 8 | 0 | 0 | no | 0.5 | 0.45 | no dnr | 40 | 73 | 8.398438 | 66 | 28 | 36 | null | null | 0.799927 | 3.599609 | 136 | null | 196 | 92 | 1,030 | null | 0 | no(M2 and SIP pres) | 0 | 1,021 | 0 |
63.33197 | male | 0 | 8 | Colon Cancer | Cancer | 1 | 9 | $25-$50k | 0 | 10,891 | null | null | 10 | white | 14.5 | 5 | 0.850952 | 0.669922 | 1 | 0 | 0 | metastatic | null | null | no dnr | 8 | 145 | 7 | 146 | 24 | 38.09375 | 596 | 3 | 0.5 | 0.899902 | 137 | 7.449219 | 98 | 4 | 3,300 | 1 | 0 | no(M2 and SIP pres) | 0 | 143 | 1 |
64.63196 | female | 0 | 14 | MOSF w/Malig | ARF/MOSF | 1 | 11 | null | 0 | 50,961 | null | null | 20.666656 | white | 20.097656 | 35 | 0.642944 | 0.541992 | 10 | 0 | 0 | metastatic | 0.1 | 0 | dnr after sadm | 3 | 41 | 2.399902 | 126 | 18 | 35.79688 | 115 | 2 | 6.599609 | 2 | 133 | 7.329102 | 42 | 31 | 360 | null | 0 | <2 mo. follow-up | 0 | 29 | 1 |
58.59799 | female | 1 | 6 | MOSF w/Malig | ARF/MOSF | 2 | 0 | under $11k | 0 | 47,649 | null | null | 48 | white | 36.5 | 44 | 0.201996 | 0.108994 | 9 | 1 | 0 | metastatic | 0.4 | 0.1 | dnr after sadm | 3 | 134 | 14.5 | 120 | 34 | 36.39844 | 226.65625 | null | 0.399963 | 2.899902 | 138 | 7.239258 | 155 | 61 | 2,070 | null | 7 | <2 mo. follow-up | 7 | 6 | 1 |
56.63199 | male | 1 | 7 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 12 | under $11k | 9 | 77,474 | null | null | 41.5 | white | 23 | 29 | 0.782959 | 0.712891 | 7 | 0 | 0 | no | null | null | dnr after sadm | 6 | 112 | 22.597656 | 67 | 20 | 36.79688 | null | 3.299805 | 1 | 1.299805 | 136 | null | 93 | 16 | 700 | null | 0 | <2 mo. follow-up | 0 | 7 | 1 |
84.50696 | male | 1 | 10 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 8 | null | 0 | 57,715 | null | null | 34.5 | white | 25.597656 | 45 | 0.629883 | 0.527954 | 8 | 0 | 0 | no | null | null | dnr after sadm | 2 | 78 | 7.199219 | 75 | 22 | 34.69531 | 450 | null | null | 1.399902 | 138 | 7.459961 | 101 | 23 | 1,450 | null | null | <2 mo. follow-up | 3.116211 | 10 | 1 |
71.02496 | female | 1 | 7 | Coma | Coma | 0 | 13 | null | 100 | 21,937 | null | null | 26.5 | black | 20.597656 | 38 | 0.242981 | 0.176971 | 1 | 0 | 0 | no | 0.05 | 0.05 | dnr after sadm | 4 | 116 | 11 | 160 | 10 | 38.19531 | 266.625 | null | null | 0.899902 | 128 | 7.489258 | 144 | 16 | 2,700 | null | 0 | <2 mo. follow-up | 0 | 7 | 1 |
55.22498 | male | 0 | 7 | COPD | COPD/CHF/Cirrhosis | 1 | null | null | 0 | 7,268 | null | null | 7 | black | 13.798828 | 27 | 0.938965 | 0.895996 | 1 | 0 | 0 | no | 0.8 | 0.6 | no dnr | 7 | 73 | 8.099609 | 130 | 22 | 37.69531 | 212.5 | 2.599609 | 1.599854 | 0.899902 | 137 | 7.389648 | 107 | 18 | 1,000 | 0 | 1 | no(M2 and SIP pres) | 1 | 1,017 | 0 |
76.81897 | male | 1 | 8 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 8 | $11-$25k | 26 | 53,023 | null | null | 39.5 | white | 38 | 56 | 0.15097 | 0.072998 | 5 | 0 | 0 | yes | 0.5 | 0.4 | dnr after sadm | 6 | 136 | 14.199219 | 126 | 30 | 37.89844 | 127.5 | 2.399902 | 0.399963 | 1.199951 | 143 | 7.399414 | 181 | 56 | 2,390 | null | 1 | <2 mo. follow-up | 1 | 8 | 1 |
69.17499 | male | 0 | 69 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 8 | null | 0 | 176,045 | 118,669.938 | 107,170 | 25 | white | 34.296875 | 41 | 0.528931 | 0.41394 | 4 | 0 | 0 | no | 0.9 | 0.8 | no dnr | 69 | 49 | 10.5 | 134 | 35 | 36.09375 | 39 | null | 0.399963 | 0.399963 | 128 | 7.419922 | 169 | 12 | 1,835 | null | 6 | adl>=4 (>=5 if sur) | 6 | 1,016 | 0 |
29.59299 | female | 0 | 20 | MOSF w/Malig | ARF/MOSF | 3 | 12 | $11-$25k | 0 | 62,432 | null | null | 20 | white | 24.5 | 51 | 0.662964 | 0.564941 | 10 | 0 | 0 | yes | 0.8 | 0.75 | no dnr | 20 | 109 | 21.5 | 60 | 8 | 38.19531 | 214.28125 | 2.799805 | null | 0.599976 | 134 | 7.439453 | 94 | 16 | 1,390 | 1 | 0 | no(M2 and SIP pres) | 0 | 507 | 1 |
66.18195 | female | 0 | 12 | Colon Cancer | Cancer | 1 | 12 | $11-$25k | 0 | 15,025 | null | null | 16 | white | 25 | 19 | 0.674927 | 0.377991 | 1 | 0 | 0 | metastatic | 0.75 | 0.5 | no dnr | 12 | 79 | 14.199219 | 66 | 22 | 36.69531 | 245.6875 | null | null | 5.599609 | 141 | 7.429688 | 207 | 50 | 483 | 0 | 0 | <2 mo. follow-up | 0 | 58 | 1 |
67.93994 | male | 0 | 9 | Lung Cancer | Cancer | 2 | 10 | under $11k | 0 | 11,082 | null | null | 9.5 | black | 21.5 | 39 | 0.599976 | 0.281982 | 1 | 0 | 0 | metastatic | 0.7 | 0.4 | no dnr | 9 | 131 | 16.5 | 154 | 25 | 34.5 | 90 | 1.5 | 0.299988 | 3.199707 | 135 | 7.439453 | 271 | 41 | 165 | 1 | 4 | no(M2 and SIP pres) | 4 | 227 | 1 |
29.09499 | male | 0 | 6 | CHF | COPD/CHF/Cirrhosis | 3 | 10 | null | 0 | 2,940 | null | null | 7 | black | 19 | 23 | 0.939941 | 0.897949 | 1 | 0 | 0 | no | null | null | no dnr | 6 | 111 | 18.398438 | 134 | 36 | 36.5 | 115 | null | 1.899902 | 1 | 142 | 7.40918 | 288 | 21 | 1,270 | 0 | 0 | SIP>=30 | 0 | 1,014 | 0 |
63.573 | male | 0 | 12 | Colon Cancer | Cancer | 1 | 3 | under $11k | 0 | 32,942 | 18,734.1562 | 17,499 | 22.5 | other | 38.59375 | 21 | 0.317993 | 0.057999 | 1 | 0 | 0 | metastatic | null | null | no dnr | 12 | 74 | 11 | 80 | 30 | 36.89844 | 246 | 2.699707 | null | 0.5 | 117 | 7.5 | 106 | 9 | 2,840 | 0 | 0 | no(M2 and SIP pres) | 0 | 1,013 | 0 |
72.71497 | female | 1 | 22 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | null | null | 0 | 67,741 | null | null | 23 | white | 27.597656 | 56 | 0.625977 | 0.521973 | 21 | 0 | 0 | no | 0.3 | 0.15 | dnr after sadm | 5 | 103 | 4.099609 | 110 | 9 | 37.89844 | 225.6875 | null | 0.699951 | 3.599609 | 143 | 7.329102 | 91 | 81 | 2,357 | null | 5 | <2 mo. follow-up | 5 | 22 | 1 |
60.01398 | male | 0 | 20 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | 12 | under $11k | 0 | 94,502 | 63,838.9688 | 52,158 | 24 | white | 30.5 | 44 | 0.667969 | 0.571899 | 5 | 0 | 0 | no | 0.6 | 0.6 | no dnr | 20 | 69 | 19.699219 | 76 | 31 | 36.59375 | 433.3125 | null | 0.899902 | 3.299805 | 138 | 7.449219 | 103 | 98 | 1,835 | null | null | no(M2 and SIP pres) | 2.320313 | 1,012 | 0 |
71.66895 | male | 0 | 9 | CHF | COPD/CHF/Cirrhosis | 2 | null | null | 0 | 10,752 | null | null | 9 | white | 21.296875 | 23 | 0.824951 | 0.714966 | 1 | 0 | 0 | no | 0.8 | 0.8 | no dnr | 9 | 73 | 1.799805 | 116 | 32 | 35.39844 | 92.29688 | null | 19.597656 | 3.799805 | 128 | 7.449219 | 177 | 106 | 4,090 | null | null | null | 2.635742 | 1,012 | 0 |
30.853 | male | 0 | 9 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 1 | $25-$50k | 0 | 14,503 | null | null | 15.5 | white | 20.296875 | 16 | 0.920898 | 0.891968 | 1 | 0 | 0 | no | 1 | 1 | no dnr | 9 | 87 | 27.398438 | 206 | 34 | 38.5 | 130 | 3.299805 | 6.899414 | 4 | 126 | 7.329102 | 668 | 86 | 107 | 0 | 0 | no(M2 and SIP pres) | 0 | 1,012 | 0 |
47.09399 | female | 0 | 29 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 17 | null | 9 | 48,037 | null | null | 21.5 | white | 22.398438 | 42 | 0.859985 | 0.810913 | 1 | 0 | 0 | no | 0.8 | 0.8 | no dnr | 29 | 53 | 16.097656 | 76 | 29 | 38 | 146.9375 | 1.799805 | 4.599609 | 1.199951 | 148 | 7.449219 | 81 | 19 | 3,770 | null | 0 | SIP>=30 | 0 | 1,012 | 0 |
49.35199 | male | 0 | 4 | CHF | COPD/CHF/Cirrhosis | 3 | 14 | >$50k | 0 | 5,036 | null | null | 6 | hispanic | 20 | 15 | 0.899902 | 0.831909 | 1 | 0 | 0 | no | null | null | no dnr | 4 | 108 | 6.899414 | 96 | 22 | 38.69531 | null | 3.599609 | 0.599976 | 0.899902 | 136 | null | 69 | 14 | 3,700 | 0 | null | no(M2 and SIP pres) | 0.494751 | 1,012 | 0 |
59.35397 | male | 0 | 29 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | 14 | null | 0 | 96,798 | 58,078.9375 | 53,137 | 27.5 | white | 22 | 32 | 0.837891 | 0.782959 | 2 | 1 | 0 | no | 0.3 | 0.2 | no dnr | 29 | 77 | 7.399414 | 54 | 22 | 36.19531 | 270 | 2.729981 | null | 4.199219 | 131 | 7.529297 | 82 | 64 | 2,190 | null | 0 | no(M2 and SIP pres) | 0 | 1,009 | 0 |
81.78796 | female | 0 | 8 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 6 | null | 9 | 30,732 | null | null | 10.5 | white | 21.398438 | 36 | 0.731934 | 0.648926 | 3 | 0 | 0 | no | 0.95 | 0.9 | no dnr | 8 | 56 | 15.5 | 106 | 10 | 36.59375 | 324 | 2.5 | 4.599609 | 3.799805 | 145 | 7.30957 | 95 | 62 | 2,367 | null | 1 | no(M2 and SIP pres) | 1 | 1,009 | 0 |
74.56494 | male | 0 | 18 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 3 | $11-$25k | 0 | 65,352 | null | null | 30.666656 | black | 29.597656 | 33 | 0.666992 | 0.569946 | 1 | 0 | 0 | no | 0.5 | 0.4 | no dnr | 18 | 103 | 8.199219 | 116 | 26 | 36.79688 | 211.40625 | 3.299805 | null | 8.199219 | 133 | 7.329102 | 184 | 103 | 1,260 | null | 0 | no(M2 and SIP pres) | 0 | 1,009 | 0 |
19.866 | female | 0 | 26 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | 12 | $25-$50k | 0 | 44,245 | 27,406.2344 | 26,054 | 15.5 | white | 24.296875 | 30 | 0.912964 | 0.880981 | 1 | 0 | 0 | no | 0.9 | 0.9 | no dnr | 26 | 73 | 3 | 114 | 24 | 36.79688 | null | 2 | 13.798828 | 0.699951 | 129 | null | 160 | 9 | 3,050 | 3 | 4 | no(M2 and SIP pres) | 4 | 1,009 | 0 |
54.17398 | male | 0 | 6 | Colon Cancer | Cancer | 1 | 12 | >$50k | 0 | 9,281 | null | null | 10 | white | 17.5 | 12 | 0.829956 | 0.630981 | 1 | 0 | 0 | metastatic | null | null | no dnr | 6 | 129 | 13.199219 | 96 | 55 | 36.09375 | 292 | null | null | 0.699951 | 135 | 7.389648 | 184 | 21 | 1,480 | 0 | 1 | no(M2 and SIP pres) | 1 | 459 | 1 |
72.38098 | male | 1 | 63 | ARF/MOSF w/Sepsis | ARF/MOSF | 3 | 16 | null | 0 | 215,817 | 140,466 | 116,142 | 30 | white | 23.199219 | 24 | 0.758911 | 0.682983 | 4 | 1 | 0 | no | 0.6 | 0.55 | dnr after sadm | 61 | 117 | 25.699219 | 106 | 30 | 35.69531 | 172.5 | null | null | 1.199951 | 143 | 7.479492 | 124 | 31 | 2,830 | 0 | 0 | null | 0 | 63 | 1 |
39.11298 | female | 1 | 65 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 12 | null | 0 | 211,744 | 147,594.125 | 121,504 | 33.5 | black | 37.398438 | 76 | 0.622925 | 0.518921 | 5 | 0 | 0 | no | 0.4 | 0.4 | dnr after sadm | 54 | 89 | 8.599609 | 94 | 24 | 36.89844 | 309.5 | 2.799805 | 0.599976 | 0.599976 | 140 | 7.40918 | 158 | 8 | 2,025 | null | 6 | null | 6 | 65 | 1 |
45.50598 | male | 1 | 13 | Cirrhosis | COPD/CHF/Cirrhosis | 3 | 15 | $25-$50k | 44 | 136,951 | null | null | 51.5 | white | 28.296875 | 46 | 0.514893 | 0.313965 | 4 | 0 | 0 | no | 0.2 | 0.2 | no dnr | 13 | 114 | 9.298828 | 70 | 24 | 36.69531 | null | null | null | 1.299805 | 141 | null | 97 | 24 | null | null | 0 | <2 mo. follow-up | 0 | 13 | 1 |
38.00098 | male | 0 | 10 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 12 | >$50k | 0 | 20,619 | null | null | 15 | white | 19.296875 | 29 | 0.916992 | 0.886963 | 1 | 0 | 0 | no | 0.9 | 0.9 | no dnr | 10 | 97 | 18.5 | 170 | 60 | 36.19531 | 216.65625 | null | 0.5 | 0.799927 | 132 | 7.469727 | 144 | 12 | 3,716 | 0 | 0 | no(M2 and SIP pres) | 0 | 1,007 | 0 |
82.57098 | female | 1 | 8 | COPD | COPD/CHF/Cirrhosis | 2 | 12 | under $11k | 0 | 18,749 | null | null | 24.5 | white | 23.5 | 40 | 0.700928 | 0.537964 | 1 | 0 | 0 | no | 0.5 | 0.5 | dnr after sadm | 4 | 48 | 0.099991 | 124 | 11 | 35.29688 | 444 | 1.199951 | 0.599976 | 1.599854 | 133 | 7.369141 | 76 | 23 | 1,430 | null | 1 | <2 mo. follow-up | 1 | 8 | 1 |
60.84299 | female | 0 | 11 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 12 | null | 0 | 54,325 | null | null | 35.5 | white | 18.097656 | 10 | 0.875977 | 0.831909 | 2 | 0 | 0 | no | 0.9 | 0.8 | no dnr | 11 | 106 | 60 | 74 | 22 | 36.39844 | 417.375 | null | null | 6.399414 | 142 | 7.319336 | 70 | 59 | null | null | 0 | no(M2 and SIP pres) | 0 | 1,006 | 0 |
47.39499 | male | 1 | 8 | ARF/MOSF w/Sepsis | ARF/MOSF | 4 | null | null | 44 | 27,011 | 18,225.9375 | 15,042 | 31 | black | 41 | 84 | 0.320984 | 0.20697 | 1 | 0 | 0 | no | 0.2 | 0.1 | dnr after sadm | 4 | 112 | 18 | 60 | 40 | 38.09375 | null | null | null | 0.799927 | 139 | null | 179 | 11 | 575 | null | null | <2 mo. follow-up | 3.375 | 8 | 1 |
57.728 | male | 0 | 6 | Lung Cancer | Cancer | 2 | 18 | >$50k | 0 | 13,046 | null | null | 17 | white | 13.798828 | 18 | 0.779907 | 0.539917 | 1 | 1 | 0 | metastatic | 0.8 | 0.6 | no dnr | 6 | 105 | 5.899414 | 86 | 24 | 37.69531 | null | null | 0.399963 | 0.599976 | 131 | null | 151 | 6 | null | 0 | 0 | null | 0 | 86 | 1 |
62.49698 | female | 1 | 3 | MOSF w/Malig | ARF/MOSF | 2 | 9 | null | 0 | 73,631 | null | null | 45 | other | 79.59375 | 104 | 0 | 0 | 1 | 1 | 0 | metastatic | 0 | 0 | dnr after sadm | 3 | 110 | 6.599609 | 96 | 16 | 35.69531 | null | null | 0.299988 | 0.799927 | 138 | null | 185 | 17 | 2,225 | null | null | <2 mo. follow-up | 1.454102 | 3 | 1 |
61.09 | female | 1 | 5 | Coma | Coma | 1 | 10 | null | 61 | 16,863 | null | null | 20 | black | 16.097656 | 25 | 0.652954 | 0.593994 | 1 | 0 | 0 | no | 0.1 | 0.1 | dnr after sadm | 5 | 73 | 51.398438 | 106 | 36 | 36.5 | 126.51562 | 2.5 | 1.599854 | 1.199951 | 150 | 7.479492 | 100 | 34 | 1,810 | null | 0 | <2 mo. follow-up | 0 | 5 | 1 |
55.017 | female | 1 | 4 | ARF/MOSF w/Sepsis | ARF/MOSF | 3 | 3 | under $11k | 9 | 27,510 | null | null | 47 | white | 55.09375 | 93 | 0.017998 | 0.004 | 6 | 0 | 0 | yes | 0 | 0 | dnr after sadm | 1 | 111 | 16.097656 | 126 | 18 | 37.79688 | 340 | 2.199707 | 1.199951 | 0.699951 | 141 | 7.529297 | 156 | 24 | 975 | null | 1 | <2 mo. follow-up | 1 | 4 | 1 |
73.86694 | male | 0 | 13 | CHF | COPD/CHF/Cirrhosis | 2 | 19 | >$50k | 0 | 60,145 | 34,741.5312 | 34,546 | 34 | white | 22.699219 | 27 | 0.772949 | 0.638916 | 3 | 0 | 0 | no | 0.8 | 0.7 | no dnr | 13 | 57 | 12.798828 | 116 | 28 | 38 | 276 | null | null | 1.099854 | 130 | 7.389648 | 176 | 20 | 2,065 | null | 0 | no(M2 and SIP pres) | 0 | 174 | 1 |
46.349 | female | 0 | 41 | COPD | COPD/CHF/Cirrhosis | 1 | 14 | $11-$25k | 0 | 104,262 | 69,474.75 | 61,195 | 26.25 | white | 19.5 | 35 | 0.929932 | 0.879883 | 1 | 0 | 0 | no | 0.5 | 0.5 | no dnr | 41 | 73 | 10.099609 | 60 | 16 | 35.69531 | null | 2.699707 | 0.5 | 0.599976 | 139 | null | 133 | 10 | 3,350 | null | 0 | no(M2 and SIP pres) | 0 | 1,004 | 0 |
33.56598 | female | 0 | 18 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 13 | $25-$50k | 0 | 67,523 | null | null | 23.333328 | white | 23.296875 | 44 | 0.876953 | 0.833984 | 4 | 0 | 0 | no | 0.8 | 0.8 | no dnr | 18 | 82 | 19.796875 | 120 | 24 | 36 | null | 3 | 0.5 | 0.699951 | 137 | null | 145 | 12 | null | null | 0 | no(M2 and SIP pres) | 0 | 1,002 | 0 |
52.44897 | male | 0 | 5 | Lung Cancer | Cancer | 1 | 11 | under $11k | 0 | 6,349 | null | null | 23 | white | 17.097656 | 13 | 0.733887 | 0.464966 | 1 | 0 | 0 | metastatic | 1 | 0.8 | no dnr | 5 | 133 | 2.199707 | 136 | 26 | 36.29688 | 308 | 2.299805 | 1 | 1.199951 | 155 | 7.509766 | 95 | 35 | 3,765 | 0 | null | no(M2 and SIP pres) | 0.494751 | 328 | 1 |
45.25098 | male | 0 | 32 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 16 | null | 0 | 144,548 | null | null | 36.25 | black | 33.695313 | 49 | 0.69397 | 0.602905 | 3 | 0 | 0 | no | 0.5 | 0.5 | no dnr | 32 | 162 | 5.799805 | 126 | 8 | 38.69531 | 303.3125 | 2.599609 | 4.5 | 3 | 136 | 7.429688 | 59 | 121 | 2,195 | null | null | no(M2 and SIP pres) | 1.995117 | 1,001 | 0 |
51.58698 | female | 0 | 12 | MOSF w/Malig | ARF/MOSF | 1 | 11 | under $11k | 0 | 23,850 | 15,265.5391 | 15,398 | 23 | other | 33.5 | 35 | 0.369995 | 0.251953 | 2 | 0 | 0 | metastatic | 0.6 | 0.3 | no dnr | 12 | 59 | 2.299805 | 124 | 40 | 38.19531 | 172.5 | null | 1 | 0.899902 | 151 | 7.479492 | 171 | 31 | 1,790 | null | 0 | null | 0 | 199 | 1 |
27.644 | male | 1 | 5 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 11 | $11-$25k | 9 | 55,573 | null | null | 37 | black | 33.898438 | 64 | 0.724976 | 0.639893 | 5 | 0 | 0 | no | 0.9 | 0.9 | no dnr | 5 | 51 | 0.299988 | 124 | 30 | 35.19531 | 168.5625 | null | null | 1.399902 | 132 | 7.349609 | 164 | 50 | 1,091 | null | null | <2 mo. follow-up | 1.954834 | 5 | 1 |
44.08197 | male | 0 | 24 | Cirrhosis | COPD/CHF/Cirrhosis | 3 | 12 | under $11k | 9 | 45,380 | 28,963.5625 | 31,141 | 20 | white | 32.59375 | 56 | 0.631958 | 0.448975 | 1 | 0 | 0 | no | 0.6 | 0.4 | no dnr | 24 | 39 | 16.296875 | 124 | 32 | 38.29688 | 113.75 | null | 0.799927 | 2.099609 | 128 | 7.339844 | 215 | 47 | 2,920 | null | 0 | no(M2 and SIP pres) | 0 | 998 | 0 |
79.67096 | male | 0 | 28 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | null | under $11k | 0 | 57,108 | 34,602.7188 | 33,933 | 25.25 | white | 21.199219 | 24 | 0.796997 | 0.72998 | 1 | 0 | 0 | no | 0.3 | 0.15 | dnr after sadm | 2 | 46 | 4.399414 | 74 | 10 | 38.89844 | 197.5 | 1.699951 | null | 0.899902 | 135 | 7.419922 | 115 | 17 | 1,830 | null | 6 | adl>=4 (>=5 if sur) | 6 | 515 | 1 |
67.09094 | male | 0 | 10 | CHF | COPD/CHF/Cirrhosis | 3 | 12 | $25-$50k | 0 | null | null | null | 26.5 | white | 16.398438 | 33 | 0.889893 | 0.816895 | 1 | 1 | 0 | no | 0.85 | 0.75 | null | null | 52 | 11.099609 | 110 | 42 | 38.69531 | 253.3125 | null | null | 1.299805 | 148 | 7.429688 | 135 | 31 | 3,065 | 0 | 4 | no(M2 and SIP pres) | 4 | 568 | 1 |
100.67896 | male | 1 | 4 | COPD | COPD/CHF/Cirrhosis | 2 | 8 | under $11k | 0 | 3,920 | null | null | 8 | black | 33.398438 | 41 | 0.22699 | 0.075989 | 1 | 1 | 0 | no | 0.5 | 0.5 | dnr after sadm | 1 | 70 | 5.399414 | 64 | 8 | 35.79688 | 177.5 | null | null | 1.299805 | 138 | 7.5 | 128 | 38 | 1,545 | null | 7 | <2 mo. follow-up | 7 | 4 | 1 |
84.13995 | female | 1 | 21 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | null | null | 0 | 105,122 | 61,753.4375 | 64,790 | 35 | white | 29.597656 | 77 | 0.526978 | 0.41095 | 9 | 0 | 0 | no | 0.4 | 0.3 | dnr after sadm | 3 | 83 | 7.099609 | 73 | 20 | 37.59375 | null | 3.299805 | 0.299988 | 1 | 143 | null | 100 | 10 | null | null | 1 | <2 mo. follow-up | 1 | 21 | 1 |
56.71198 | female | 1 | 14 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 10 | $25-$50k | 0 | 88,913 | 55,612.4375 | 46,654 | 44.666657 | white | 32.59375 | 56 | 0.612915 | 0.506958 | 11 | 1 | 0 | no | 0.5 | 0.4 | dnr after sadm | 12 | 134 | 17.699219 | 224 | 8 | 37.89844 | 330 | 2.199707 | 0.5 | 0.899902 | 135 | 7.489258 | 85 | 16 | 2,750 | null | 1 | <2 mo. follow-up | 1 | 14 | 1 |
53.00497 | male | 0 | 4 | Lung Cancer | Cancer | 1 | 12 | >$50k | 0 | 3,597 | 2,311.5449 | 1,932 | 10 | white | 16.898438 | 19 | 0.737915 | 0.470947 | 1 | 0 | 0 | metastatic | 0.8 | 0.5 | no dnr | 4 | 49 | 17 | 134 | 12 | 38.59375 | 140 | null | null | 0.5 | 133 | 7.359375 | 150 | 16 | 665 | null | 0 | null | 0 | 107 | 1 |
72.31494 | female | 1 | 13 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | 3 | under $11k | 37 | 75,777 | 48,117.125 | 38,192 | 47 | black | 27.699219 | 45 | 0.511963 | 0.394958 | 4 | 1 | 0 | no | 0.3 | 0.2 | dnr after sadm | 12 | 139 | 16 | 114 | 32 | 38.59375 | 324 | null | 0.599976 | 0.5 | 136 | 7.449219 | 278 | 19 | 5,190 | null | 6 | <2 mo. follow-up | 6 | 13 | 1 |
70.31097 | male | 0 | 30 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 16 | $25-$50k | 0 | 70,800 | 52,140.75 | 42,268 | 21.75 | white | 23.597656 | 32 | 0.794922 | 0.726929 | 1 | 0 | 0 | no | 0.6 | 0.5 | no dnr | 30 | 61 | 11.099609 | 76 | 31 | 38.19531 | 191.40625 | 2.899902 | 2.599609 | 4.699219 | 142 | 7.379883 | 80 | 90 | 2,215 | null | null | no(M2 and SIP pres) | 2.033691 | 992 | 0 |
61.72498 | female | 1 | 6 | Coma | Coma | 0 | 9 | under $11k | 89 | 38,154 | 26,825.9531 | 20,579 | 44 | white | 20.199219 | 31 | 0.332947 | 0.260986 | 5 | 0 | 0 | no | 0 | 0 | dnr after sadm | 2 | 107 | 18 | 146 | 7 | 38.29688 | 292 | 3.399902 | 0.5 | 1.299805 | 147 | 7.459961 | 376 | 23 | 1,660 | null | null | <2 mo. follow-up | 2.086914 | 6 | 1 |
68.13696 | female | 0 | 4 | Colon Cancer | Cancer | 3 | 12 | >$50k | 0 | 7,693 | 4,762.9375 | 3,260 | 7 | white | 16.296875 | 12 | 0.820923 | 0.613892 | 1 | 1 | 0 | metastatic | null | null | no dnr | 4 | 108 | 16.5 | 76 | 24 | 36.5 | 164 | 4.399414 | 0.699951 | 1 | 137 | 7.30957 | 126 | 22 | 2,050 | null | null | no(M2 and SIP pres) | 1.982178 | 163 | 1 |
81.94897 | female | 0 | 14 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 10 | under $11k | 0 | 51,340 | 32,087.4375 | 32,062 | 21 | white | 26.296875 | 30 | 0.610962 | 0.504883 | 14 | 0 | 0 | no | 0 | 0 | no dnr | 14 | 62 | 5.699219 | 110 | 46 | 36.09375 | 165.6875 | null | null | 4.899414 | 128 | 7.399414 | 148 | 76 | 1,495 | 0 | 0 | no(M2 and SIP pres) | 0 | 991 | 0 |
79.034 | male | 0 | 10 | COPD | COPD/CHF/Cirrhosis | 1 | 5 | $11-$25k | 0 | 14,735 | 9,159.4531 | 9,445 | 10.5 | white | 18.5 | 22 | 0.810913 | 0.69397 | 1 | 0 | 0 | no | 0.88 | 0.8 | no dnr | 10 | 117 | 2.899902 | 116 | 25 | 36.19531 | 190 | 3.099609 | 0.199982 | 0.199982 | 132 | 7.509766 | 213 | 18 | 3,375 | 1 | 2 | no(M2 and SIP pres) | 2 | 991 | 0 |
69.60699 | female | 0 | 3 | Lung Cancer | Cancer | 1 | 13 | under $11k | 0 | 5,958 | 2,977.6484 | 1,305 | 3 | white | 12.798828 | 11 | 0.774902 | 0.530884 | 1 | 0 | 0 | metastatic | 0.9 | 0.7 | no dnr | 3 | 128 | 32.5 | 134 | 8 | 35.79688 | 266.625 | 1.899902 | 0.799927 | 0.699951 | 141 | 7.459961 | 159 | 25 | 800 | 2 | null | SIP>=30 | 1.838867 | 324 | 1 |
72.00494 | female | 0 | 6 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | 6 | null | 9 | 68,144 | 47,068.375 | 41,204 | 32 | white | 35 | 59 | 0.379944 | 0.260986 | 24 | 0 | 0 | no | 0.2 | 0.5 | dnr after sadm | 3 | 73 | 11.298828 | 50 | 14 | 36.79688 | null | 3.099609 | 0.599976 | 0.5 | 136 | null | 92 | 11 | 450 | null | 3 | <2 mo. follow-up | 3 | 7 | 1 |
54.65799 | male | 0 | 6 | Colon Cancer | Cancer | 1 | null | null | 0 | 8,430 | 4,578.5547 | 2,552 | 11 | white | 13.398438 | 10 | 0.873901 | 0.716919 | 1 | 0 | 0 | metastatic | 0.8 | 0.6 | no dnr | 6 | 103 | 10.199219 | 140 | 24 | 36.5 | 225.90625 | null | null | 0.799927 | 136 | 7.459961 | 108 | 11 | 0 | null | null | null | 1.643311 | 330 | 1 |
36.38098 | male | 0 | 18 | ARF/MOSF w/Sepsis | ARF/MOSF | 3 | 8 | under $11k | 0 | 41,443 | 27,296.5 | 26,221 | 22 | white | 22.597656 | 36 | 0.881958 | 0.839966 | 3 | 0 | 0 | no | 0.65 | 0.6 | no dnr | 18 | 70 | 4 | 80 | 28 | 36.09375 | null | null | 3.699707 | 1.199951 | 139 | null | 88 | 13 | 3,670 | 5 | 4 | SIP>=30 | 4 | 989 | 0 |
72.56097 | female | 1 | 32 | ARF/MOSF w/Sepsis | ARF/MOSF | 3 | 12 | $11-$25k | 0 | 263,761 | 154,728.25 | 154,703 | 35.25 | white | 29.796875 | 66 | 0.560913 | 0.448975 | 40 | 1 | 0 | no | 0.5 | 0.4 | dnr after sadm | 28 | 111 | 23.296875 | 110 | 10 | 35.89844 | 306.625 | 2.099609 | 1.399902 | 1.199951 | 135 | null | 253 | 8 | null | null | 0 | <2 mo. follow-up | 0 | 32 | 1 |
69.224 | female | 0 | 74 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 11 | null | 0 | 112,202 | 73,917.9375 | 89,256 | 14 | white | 27 | 42 | 0.702881 | 0.612915 | 4 | 0 | 0 | no | 0.75 | 0.7 | no dnr | 74 | 69 | 20.796875 | 116 | 45 | 36.89844 | 210 | 6 | null | 1.699951 | 134 | 7.5 | 101 | 59 | 2,885 | 0 | null | no(M2 and SIP pres) | 0.494751 | 988 | 0 |
69.41296 | male | 1 | 3 | Coma | Coma | 2 | 14 | null | 100 | 22,805 | 13,870.9531 | 11,851 | 30 | white | 76.6875 | 78 | 0 | 0 | 2 | 1 | 0 | no | 0 | 0 | dnr after sadm | 3 | 124 | 10.5 | 50 | 52 | 38.69531 | 121.42188 | null | 1.699951 | 0.899902 | 132 | 7.379883 | 223 | 10 | 3,115 | null | null | <2 mo. follow-up | 1.676025 | 3 | 1 |
92.07898 | male | 1 | 17 | Coma | Coma | 1 | 4 | null | 100 | 21,422 | 15,316.3672 | 13,817 | 15.333328 | black | 26.796875 | 49 | 0.014 | 0.006 | 1 | 0 | 0 | no | 0.1 | 0.05 | dnr after sadm | 2 | 139 | 13.5 | 52 | 20 | 36 | null | null | 0.399963 | 1.699951 | 141 | null | 156 | 26 | 4,530 | null | 3 | <2 mo. follow-up | 3 | 17 | 1 |
79.60596 | female | 1 | 15 | ARF/MOSF w/Sepsis | ARF/MOSF | 4 | null | under $11k | 9 | 124,058 | 84,398.0625 | 67,341 | 34 | white | 22.898438 | 43 | 0.662964 | 0.565918 | 17 | 1 | 0 | no | 0.25 | 0.2 | no dnr | 15 | 109 | 5.199219 | 106 | 28 | 38.09375 | 240 | 3.099609 | 0.799927 | 0.799927 | 136 | 7.5 | 105 | 7 | 2,175 | null | 1 | <2 mo. follow-up | 1 | 15 | 1 |
60.08197 | female | 1 | 6 | Coma | Coma | 2 | null | null | 44 | 20,261 | 12,103.0781 | 11,114 | 35 | white | 31.097656 | 46 | 0.335999 | 0.263977 | 1 | 0 | 0 | no | 0.25 | 0.1 | dnr after sadm | 3 | 109 | 11.398438 | 130 | 42 | 38.19531 | 328.5625 | 2.399902 | 0.5 | 1.199951 | 146 | 7.40918 | 101 | 11 | 5,445 | null | null | <2 mo. follow-up | 2.287598 | 6 | 1 |
43.60599 | male | 0 | 15 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 13 | >$50k | 0 | 47,040 | null | null | 29 | black | 24.796875 | 39 | 0.859985 | 0.81189 | 1 | 0 | 0 | no | 0.5 | 0.5 | no dnr | 15 | 130 | 12.699219 | 105 | 22 | 36 | null | null | null | 1.199951 | 138 | null | 102 | 10 | null | null | 0 | no(M2 and SIP pres) | 0 | 985 | 0 |
52.90598 | female | 0 | 185 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | 12 | null | 0 | 387,733 | 289,438.25 | 295,038 | 38.25 | white | 18.097656 | 36 | 0.876953 | 0.833984 | 6 | 1 | 0 | no | 0.5 | 0.25 | no dnr | 185 | 66 | 14.898438 | 120 | 30 | 38 | 260 | null | null | 1.299805 | 135 | 7.459961 | 362 | 17 | 2,130 | null | 5 | null | 5 | 441 | 1 |
56.36099 | male | 0 | 4 | Lung Cancer | Cancer | 0 | 14 | $25-$50k | 0 | 3,364 | 2,276.2129 | 1,885 | 4 | white | 5.899414 | 5 | 0.878906 | 0.726929 | 1 | 0 | 0 | metastatic | 0.75 | 0.6 | no dnr | 4 | 75 | 13 | 72 | 6 | 36.19531 | 180 | 2.299805 | null | 1.199951 | 141 | 7.449219 | 168 | 21 | 1,925 | null | null | no(M2 and SIP pres) | 1.554688 | 292 | 1 |
46.17398 | female | 1 | 39 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | null | null | 9 | 191,962 | 110,909.062 | 111,697 | 35 | other | 30.199219 | 38 | 0.738892 | 0.656982 | 2 | 0 | 0 | no | 0.3 | 0.25 | no dnr | 39 | 51 | 12.798828 | 114 | 8 | 36.79688 | 286.625 | null | null | 1.299805 | 133 | 7.429688 | 138 | 11 | 3,760 | null | 0 | <2 mo. follow-up | 0 | 39 | 1 |
75.55597 | male | 0 | 10 | Colon Cancer | Cancer | 2 | 11 | $11-$25k | 0 | 24,408 | 13,726.4297 | 14,629 | 23 | other | 38.5 | 34 | 0.272949 | 0.039993 | 1 | 1 | 0 | metastatic | null | null | no dnr | 10 | 122 | 17.398438 | 56 | 26 | 36.09375 | 177.125 | 2 | 0.699951 | 0.699951 | 141 | 7.419922 | 205 | 14 | 2,180 | 1 | 0 | no(M2 and SIP pres) | 0 | 339 | 1 |
74.06696 | female | 0 | 63 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 18 | $25-$50k | 44 | 351,646 | 235,729.75 | 203,126 | 32 | white | 29.597656 | 48 | 0.330994 | 0.215973 | 39 | 0 | 0 | no | 0 | 0 | dnr after sadm | 1 | 117 | 11.099609 | 104 | 22 | 38.09375 | null | null | 0.899902 | 0.799927 | 136 | null | 126 | 6 | 1,200 | null | null | adl>=4 (>=5 if sur) | 2.467773 | 984 | 0 |
77.97095 | male | 0 | 4 | CHF | COPD/CHF/Cirrhosis | 2 | 7 | under $11k | 0 | 12,064 | 6,601.418 | 6,840 | 21 | white | 27.199219 | 47 | 0.700928 | 0.53894 | 1 | 0 | 0 | no | 0.95 | 0.9 | no dnr | 4 | 110 | 13.099609 | 114 | 10 | 36.19531 | 280 | null | null | 1.399902 | 147 | 7.419922 | 149 | 32 | 1,190 | 1 | 0 | null | 0 | 757 | 1 |
64.79395 | male | 1 | 5 | MOSF w/Malig | ARF/MOSF | 2 | 12 | under $11k | 41 | 48,334 | null | null | 52 | white | 53.195313 | 95 | 0 | 0 | 15 | 0 | 0 | metastatic | 0.15 | 0.05 | dnr after sadm | 3 | 55 | 10.199219 | 120 | 34 | 35.89844 | 154.28125 | null | null | 3.799805 | 138 | 7.229492 | 83 | 58 | 65 | null | 0 | <2 mo. follow-up | 0 | 5 | 1 |
69.62396 | male | 0 | 5 | Colon Cancer | Cancer | 1 | 14 | >$50k | 0 | 8,843 | 4,625.3203 | 2,360 | 16 | white | 25 | 24 | 0.664917 | 0.363953 | 1 | 0 | 0 | metastatic | null | null | no dnr | 5 | 121 | 10.099609 | 124 | 16 | 38.89844 | 184 | null | 3.799805 | 1.799805 | 149 | 7.479492 | 151 | 55 | 5,600 | 1 | 1 | no(M2 and SIP pres) | 1 | 78 | 1 |
66.41498 | female | 1 | 12 | ARF/MOSF w/Sepsis | ARF/MOSF | 3 | 11 | under $11k | 0 | 63,235 | 43,191.6875 | 33,924 | 49 | white | 36 | 67 | 0.514893 | 0.398987 | 3 | 0 | 0 | no | 0.3 | 0.25 | dnr after sadm | 10 | 69 | 9.298828 | 114 | 33 | 38 | 233.3125 | 2.699707 | 0.899902 | 0.899902 | 134 | 7.489258 | 135 | 17 | 2,980 | null | 6 | <2 mo. follow-up | 6 | 12 | 1 |
43.88797 | male | 1 | 3 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 14 | under $11k | 0 | 33,859 | 20,129.8125 | 19,062 | 40 | white | 78.390625 | 101 | 0 | 0 | 6 | 0 | 0 | no | null | null | dnr after sadm | 2 | 73 | 11.599609 | 66 | 43 | 36.89844 | 171.40625 | null | null | 0.599976 | 143 | 7.459961 | 144 | 19 | 5,270 | null | null | <2 mo. follow-up | 1.300293 | 3 | 1 |
64.60498 | female | 0 | 11 | ARF/MOSF w/Sepsis | ARF/MOSF | 3 | 12 | $11-$25k | 26 | 20,922 | 14,122.8906 | 12,004 | 19.5 | white | 34.195313 | 67 | 0.324951 | 0.209991 | 6 | 0 | 0 | yes | 0.8 | 0.75 | no dnr | 11 | 77 | 11.898438 | 84 | 10 | 38.39844 | 205 | null | null | 0.599976 | 135 | 7.359375 | 131 | 7 | 4,025 | 1 | 1 | no(M2 and SIP pres) | 1 | 685 | 1 |
25.83699 | male | 0 | 13 | ARF/MOSF w/Sepsis | ARF/MOSF | 0 | 16 | null | 0 | 37,859 | 26,204.4531 | 19,260 | 36 | white | 28.898438 | 36 | 0.860962 | 0.812988 | 1 | 0 | 0 | no | 0.7 | 0.7 | no dnr | 13 | 55 | 17.597656 | 100 | 9 | 35.69531 | 120 | null | 2.5 | 6.399414 | 132 | 7.439453 | 163 | 52 | 0 | null | 0 | no(M2 and SIP pres) | 0 | 979 | 0 |
53.27597 | male | 0 | 5 | Colon Cancer | Cancer | 1 | null | null | 0 | 4,133 | 2,510.0586 | 1,991 | 11 | white | 15.599609 | 11 | 0.853882 | 0.675903 | 1 | 0 | 0 | metastatic | 0.7 | 0.3 | no dnr | 5 | 117 | 11.199219 | 64 | 28 | 36.89844 | null | 3.899902 | 0.899902 | 0.699951 | 138 | null | 269 | 14 | 2,575 | null | null | null | 1.698486 | 112 | 1 |
76.84094 | female | 1 | 29 | ARF/MOSF w/Sepsis | ARF/MOSF | 1 | 12 | under $11k | 0 | 197,568 | 125,466.125 | 105,323 | 50.25 | white | 31.597656 | 60 | 0.522949 | 0.407959 | 8 | 0 | 0 | no | 0.5 | 0.125 | dnr after sadm | 29 | 0 | 15.699219 | 0 | 8 | 35.39844 | 172.5 | 1 | 1.099854 | 2.699707 | 129 | 7.299805 | 393 | 40 | 0 | null | 0 | <2 mo. follow-up | 0 | 29 | 1 |
73.45099 | male | 0 | 17 | ARF/MOSF w/Sepsis | ARF/MOSF | 2 | null | null | 61 | 49,163 | 31,625.6719 | 30,657 | 13.333328 | white | 21.296875 | 28 | 0.56189 | 0.448975 | 4 | 0 | 0 | no | 0.05 | 0 | dnr after sadm | 4 | 137 | 12.898438 | 66 | 12 | 38.19531 | 222.84375 | null | null | 0.899902 | 150 | 7.5 | 113 | 20 | 4,445 | null | 6 | <2 mo. follow-up | 6 | 28 | 1 |
54.74298 | male | 0 | 11 | Lung Cancer | Cancer | 1 | 12 | $25-$50k | 0 | 12,573 | 7,762.1016 | 7,355 | 9 | white | 24.597656 | 31 | 0.560913 | 0.238983 | 1 | 0 | 0 | metastatic | null | null | no dnr | 11 | 36 | 1.199951 | 30 | 33 | 37.59375 | 93.875 | null | null | 1.899902 | 143 | 7.40918 | 98 | 32 | 110 | null | 0 | adl>=4 (>=5 if sur) | 0 | 92 | 1 |
68.35297 | male | 0 | 9 | Lung Cancer | Cancer | 1 | null | null | 0 | 10,104 | 6,418.5742 | 6,909 | 11 | white | 12.798828 | 21 | 0.775879 | 0.532959 | 1 | 0 | 0 | metastatic | null | null | no dnr | 9 | 76 | 9.898438 | 56 | 8 | 36 | 332 | null | null | 1.299805 | 131 | 7.379883 | 116 | 17 | 1,165 | null | 0 | <2 mo. follow-up | 0 | 36 | 1 |
66.00995 | male | 0 | 11 | CHF | COPD/CHF/Cirrhosis | 4 | 14 | $11-$25k | 0 | 16,025 | 12,553.1641 | 7,611 | 11 | white | 12.298828 | 25 | 0.901978 | 0.834961 | 1 | 1 | 0 | yes | 0.75 | 0.5 | no dnr | 11 | 153 | 15.898438 | 140 | 14 | 36.89844 | 280 | 4 | 0.399963 | 0.599976 | 143 | 7.479492 | 186 | 23 | 2,510 | 0 | null | no(M2 and SIP pres) | 0.494751 | 430 | 1 |
62.15698 | female | 0 | 18 | ARF/MOSF w/Sepsis | ARF/MOSF | 4 | 8 | under $11k | 0 | 43,691 | 27,075.0625 | 25,739 | 22 | black | 38.195313 | 53 | 0.526978 | 0.41095 | 1 | 0 | 0 | no | 0.7 | 0.6 | no dnr | 18 | 109 | 6.399414 | 170 | 10 | 38.69531 | 210 | 1.5 | 1.899902 | 0.5 | 137 | 7.40918 | 94 | 12 | 1,963 | null | null | no(M2 and SIP pres) | 3.624512 | 977 | 0 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.